Cabometyx, Exelixis
FDA Grants Cabometyx New Indication for HCC
The FDA granted a new indication to cabozantinib (Cabometyx, Exelixis) for patients with hepatocellular carcinoma ...
JANUARY 16, 2019
Cabometyx Approved for First-Line Treatment of Advanced RCC
The FDA has granted regular approval to cabozantinib (Cabometyx, Exelixis) for the treatment of patients with ...
DECEMBER 20, 2017
Is Cabozantinib a Standard of Care for Advanced RCC?
A final report from the Phase III METEOR trial makes a solid case that cabozantinib is a new standard of care in ...
MAY 9, 2017
Load more